AGP Executive Report
Last update: 4 hours agoDementia & Inflammation: A new meta-analysis links four common dementia types to distinct immune/inflammatory profiles, raising hopes for more targeted treatments. Public Health Access: Nigeria’s NPHCDA mapped “zero-dose” hotspots to guide targeted vaccination using an identify-enumerate-vaccinate approach. Drug Pricing & Patents: U.S. lawmakers advanced insulin cost caps ($35/month) and moved to curb FDA citizen-petition tactics that can delay generics and biosimilars. New Narcolepsy Option: The FDA approved Orzeyful (oveporexton), the first medicine aimed at treating the full symptom range of narcolepsy type 1 by restoring orexin signaling. Food Allergy Breakthrough: A study suggests omalizumab-facilitated oral immunotherapy can help many multi-food allergy patients start at maintenance dosing with fewer escalation steps. Gut Microbiome Therapy: Early results from “poop pill” fecal transplants indicate some severe peanut-allergy patients may gain tolerance, with antibiotics potentially improving transfer. Women’s Health: Research found type 2 diabetes is tied to more severe menopause symptoms, underscoring the need to manage cardiovascular risk during the transition. Care Delivery & Equity: Experts discuss how to expand access to bladder-sparing intravesical therapies despite logistical and reimbursement barriers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27372611-932839304-75626657a08ac97c4a5989e9241c1a78a7eeccd6-1280x720-200x113.png)
